Drug
Belzutifan
Belzutifan: highest development phase Phase 3, developed by Merck. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Belzutifan NCT04586231 | Phase 3 | Carcinoma, Renal Cell |
| Belzutifan NCT04736706 | Phase 3 | Carcinoma, Renal Cell |
| Belzutifan NCT07489495 | Phase 3 | Carcinoma, Renal Cell |
| Belzutifan NCT04924075 | Phase 2 | Pheochromocytoma/Paraganglioma |
| Belzutifan NCT07700758 | Phase 2 | Malignant Neoplasm |
| Belzutifan NCT07049926 | Phase 1/2 | Renal Cell Carcinoma |
Latest
No recent events.
Follow Belzutifan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.